Home Lymphoma Amplifying Responses With ADCs and Checkpoint Inhibitors in Hodgkin Lymphoma

Amplifying Responses With ADCs and Checkpoint Inhibitors in Hodgkin Lymphoma

79
0

Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope

Matthew G. Mei, MD

Doxorubicin, belomycin, vinblastine, and dacarbazine (ABVD) and doxorubicin, vinblastine, and dacarbazine (AVD) plus brentuximab vedotin (Adcetris; A+AVD) are both viable frontline treatment options for patients with advanced-stage Hodgkin lymphoma, said Matthew G. Mei, MD, and the decision between the two can be based on the extent of disease and, potentially, cost.

… to read the full story

This site uses Akismet to reduce spam. Learn how your comment data is processed.